BioXcel Therapeutics (BTAI) Depreciation & Amortization (CF) (2017 - 2026)

BioXcel Therapeutics' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $58000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 23.68% year-over-year to $58000.0 in Q1 2026; TTM through Mar 2026 was $282000.0, a 8.14% decrease from a year earlier, with the FY2025 full-year figure at $300000.0, down 2.91% from the prior year.
• Depreciation & Amortization (CF) retreated to $58000.0 in Q1 2026 per BTAI's latest filing, from $74000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $85000.0 in Q3 2022 and bottomed at $58000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $77000.0 (2022), against an average of $77176.5.
• Across the five-year window, Depreciation & Amortization (CF) gained 18.46% in 2022 and dropped 23.68% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $81000.0 in 2022, then fell by 3.7% to $78000.0 in 2023, then retreated by 1.28% to $77000.0 in 2024, then slipped by 3.9% to $74000.0 in 2025, then retreated by 21.62% to $58000.0 in 2026.
• Per Business Quant, the three latest BTAI Depreciation & Amortization (CF) figures stand at $58000.0 (Q1 2026), $74000.0 (Q4 2025), and $75000.0 (Q3 2025).